Reduction in bradykinin generation during leukocytapheresis using novel cellsorbaTM CS-180S: Effects of changing the filling solution

• Published in: Journal of clinical apheresis Vol. 29; no. 2; pp. 90 - 96
• Main Authors: Yamada, Risa, Kusaoi, Makio, Murayama, Go, Yasui, Misa, Hishinuma, Ruka, Nemoto, Takuya, Hohtatsu, Katsura, Kageyama, Michiaki, Kawamoto, Toshio, Sugimoto, Kaoru, Sekiya, Fumio, Kon, Takayuki, Ogasawara, Michihiro, Kempe, Kazuo, Yamaji, Ken, Tsuda, Hiroshi, Takasaki, Yoshinari
• Format: Journal Article
• Language: English
• Published: Worcester Blackwell Publishing Ltd 01.04.2014; Wiley Subscription Services, Inc
• Subjects: bradykinin generation; leukocytapheresis; novel column
• ISSN: 0733-2459; 1098-1101
• DOI: 10.1002/jca.21297

We evaluated the bradykinin generation level during leukocytapheresis (LCAP) using novel CellsorbaTM CS‐180S, which has sodium pyrosulfite and sodium carbonate as a filling solution. Subjects of this study were 14 rheumatoid arthritis patients. Regardless of the type of anticoagulant used, bradykinin levels were lower with the novel CS‐180S than with the conventional CS‐180S (28.7 ± 53.3 vs. 8.0 ± 2.7 as the mean ± standard deviation). When anticoagulants other than nafamostat mesilate were used with the conventional CS‐180S, bradykinin levels increased at the column outlet compared with the column inlet, and adverse effects of bradykinin were seen in several cases. In contrast, bradykinin levels remained low and no bradykinin‐associated adverse events were observed with the novel CS‐180S. We recommend using the novel column instead of the conventional column in the treatment of LCAP. J. Clin. Apheresis 29:90–96, 2014. © 2013 Wiley Periodicals, Inc.